Examining the use of cannabidiol and delta‐9‐tetrahydrocannabinol‐based medicine among individuals diagnosed with dementia living within residential aged care facilities: Results of a double‐blind randomised crossover trial
Australasian Journal on Ageing · 2023-12 · 42 (4) · 698-709
DOI: 10.1111/ajag.13224 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Australasian Journal on Ageing, online erschienen am 15.06.2023. Verfasst von Amanda Timler und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Health Research, University of Notre Dame Australia, Fremantle, WA, USA. Hauptthemen laut MEDLINE: Cannabidiol, Dementia, Cannabinoids. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MGC Pharmaceuticals.
Themen: Langzeitpflege, Gerontologische Pflege, Demenz
Abstract (Originalsprache)
Objective
Dementia affects individuals older than 65 years. Currently, residential aged care facilities (RACF) use psychotropic medications to manage behavioural and neuropsychiatric symptoms of dementia (BPSD), which are recommended for short‐term use and have substantial side effects, including increased mortality. Cannabinoid‐based medicines (CBM) have some benefits that inhibit BPSD and cause minimal adverse effects (AEs), yet limited research has been considered with this population. The study aimed to determine a tolerable CBM dose (3:2 delta‐9‐tetrahydrocannabinol:cannabidiol), and assessed its effect on BPSD, quality of life (QoL) and perceived pain.
Methods
An 18‐week randomised, double‐blinded, crossover trial was conducted. Four surveys, collected on seven occasions, were used to measure changes in BPSD, QoL and pain. Qualitative data helped to understand attitudes towards CBM. General linear mixed models were used in the analysis, and the qualitative data were synthesised.
Results
Twenty‐one participants (77% female participants, mean age 85) took part in the trial. No significant differences were seen between the placebo and CBM for behaviour, QOL or pain, except a decrease in agitation at the end of treatment in favour of CBM. The qualitative findings suggested improved relaxation and sleep among some individuals. Post hoc estimates on the data collected suggested that 50 cases would draw stronger conclusions on the Neuropsychiatric Inventory.
Conclusions
The study design was robust, rigorous and informed by RACF. The medication appeared safe, with minimal AEs experienced with CBM. Further studies incorporating larger samples when considering CBM would allow researchers to investigate the sensitivity of detecting BPSD changes within the complexity of the disease and concomitant with medications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Health Research, University of Notre Dame Australia, Fremantle, WA, USA.
- Emerald Clinics, Fremantle, WA, USA.
ORCID-Profile: Amanda Timler
Förderung
- MGC Pharmaceuticals
Zitieren
APA
Timler, A., Bulsara, C., Bulsara, M., Vickery, A., Jacques, A., & Codde, J. (2023). Examining the use of cannabidiol and delta‐9‐tetrahydrocannabinol‐based medicine among individuals diagnosed with dementia living within residential aged care facilities: Results of a double‐blind randomised crossover trial. Australasian Journal on Ageing, 42(4), 698-709. https://doi.org/10.1111/ajag.13224
Vancouver
Timler A, Bulsara C, Bulsara M, Vickery A, Jacques A, Codde J. Examining the use of cannabidiol and delta‐9‐tetrahydrocannabinol‐based medicine among individuals diagnosed with dementia living within residential aged care facilities: Results of a double‐blind randomised crossover trial. Australasian Journal on Ageing. 2023;42(4):698-709. doi:10.1111/ajag.13224
BibTeX
@article{Timler2023,
author = {Timler, Amanda and Bulsara, Caroline and Bulsara, Max and Vickery, Alistair and Jacques, Angela and Codde, Jim},
title = {Examining the use of cannabidiol and delta‐9‐tetrahydrocannabinol‐based medicine among individuals diagnosed with dementia living within residential aged care facilities: Results of a double‐blind randomised crossover trial},
journal = {Australasian Journal on Ageing},
year = {2023},
volume = {42},
number = {4},
pages = {698--709},
doi = {10.1111/ajag.13224}
}
EUVIMED